Protection against wild-type murine gammaherpesvirus-68 latency by a latency-deficient mutant
- 1 January 2004
- journal article
- Published by Microbiology Society in Journal of General Virology
- Vol. 85 (1) , 131-135
- https://doi.org/10.1099/vir.0.19592-0
Abstract
A murine gammaherpesvirus-68 (MHV-68) mutant with deregulated transcription of its ORF50 transactivator was severely impaired in latency establishment. The deregulated virus showed reduced immunogenicity, probably reflecting a lower antigen load. However, it still elicited effective immunity to a subsequent wild-type (WT) virus challenge. Infection was not completely prevented, but was very substantially reduced in extent and the long-term level of WT viral DNA in lungs and spleens remained low. Thus latency-deficient MHV-68 illustrates a possible general approach to creating attenuated gammaherpesvirus vaccines that can protect against pathogenic WT infections.Keywords
This publication has 30 references indexed in Scilit:
- Multiple Epstein-Barr Virus Infections in Healthy IndividualsJournal of Virology, 2003
- Effective Vaccination against Long-Term Gammaherpesvirus LatencyJournal of Virology, 2003
- Murine Gammaherpesvirus 68 Lacking Thymidine Kinase Shows Severe Attenuation of Lytic Cycle Replication In Vivo but Still Establishes LatencyJournal of Virology, 2003
- The wood mouse is a natural host for Murid herpesvirus 4Journal of General Virology, 2003
- Humoral Immune Response and Protection from Viral Infection in Mice Vaccinated with Inactivated MHV-68: Effects of Type I InterferonJournal of Interferon & Cytokine Research, 2002
- Promoter Sequences Required for Reactivation of Epstein-Barr Virus from LatencyJournal of Virology, 2002
- K3-mediated evasion of CD8+ T cells aids amplification of a latent γ-herpesvirusNature Immunology, 2002
- Vaccines against persistent DNA virus infectionsBritish Medical Bulletin, 2002
- Murine gamma-herpesvirus 68 glycoprotein 150 protects against virus-induced mononucleosis: A model system for gamma-herpesvirus vaccinationVaccine, 1999
- Protection of cottontop tamarins against Epstein–Barr virus-induced malignant lymphoma by a prototype subunit vaccineNature, 1985